LEHAR; Joseph

Patent Applications and Registrations

Patent applications and USPTO patent grants for LEHAR; Joseph.The latest application filed is for "combination of pi3k inhibitor and c-met inhibitor".

Company Profile

5.4.25

LEHAR; Joseph - Lexington MA
LEHAR; Joseph - Cambridge MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Combination Of Pi3k Inhibitor And C-met Inhibitor App 20220280523 - CAPONIGRO; Giordano ; et al.	2022-09-08
Mdm2 Inhibitors And Combinations Thereof App 20210260059 - CAPONIGRO; Giordano ; et al.	2021-08-26
Combination Of Ribociclib And Dabrafenib For Treating Or Preventing Cancer App 20210186973 - CAPONIGRO; Giordano ; et al.	2021-06-24
Combination Of Pi3k Inhibitor And C-met Inhibitor App 20200253980 - Kind Code	2020-08-13
Combinations Of The Cdk4/6 Inhibitor Lee011 And The Mek1/2 Inhibitor Trametinib, Optionally Further Comprising The Pi3k Inhibito App 20190365741 - Caponigro; Giordano ; et al.	2019-12-05
Combination of PI3K inhibitor and c-MET inhibitor App 20190350935 - Caponigro; Giordano ; et al.	2019-11-21
Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer Grant 10,328,066 - Caponigro , et al.	2019-06-25
Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer Grant 10,328,065 - Caponigro , et al.	2019-06-25
Combination of PI3K Inhibitor and C-Met Inhibitor App 20190083500 - Caponigro; Giordano ; et al.	2019-03-21
Mdm2 Inhibitors And Combinations Thereof App 20190060309 - Halilovic; Ensar ; et al.	2019-02-28
Combination Therapy Using Pi3k Inhibitor And Mdm2 Inhibitor App 20180318275 - CAPONIGRO; Giordano ; et al.	2018-11-08
Pharmaceutical Combination Comprising (a) The Alpha-isoform Specific Pi3k Inhibitor Alpelisib (byl719) And (b) An Akt Inhibitor, Preferably Mk-2206, Afuresertib Or Uprosertib, And The Use Thereof In The Treatment/prevention Of Cancer App 20180256557 - Caponigro; Giordano ; et al.	2018-09-13
Combination Of Ribociclib And Dabrafenib For Treating Or Preventing Cancer App 20180250302 - CAPONIGRO; Giordano ; et al.	2018-09-06
Pharmaceutical Combination Comprising The Pi3k Inhibitor Alpelisib And The B-raf Inhibitor Dabrafenib; The Use Of Such Combination In The Treatment Or Prevention Of Cancer App 20180243279 - Caponigro; Giordano ; et al.	2018-08-30
A Pharmaceutical Combination Comprising The Pi3k Inhibitor Alpelisib And The Cdk4/6 Inhibitor Ribociclib, And The Use Thereof In The Treatment/prevention Of Cancer App 20180243280 - Caponigro; Giordano ; et al.	2018-08-30
Pharmaceutical Combinations Comprising (a) The Cyclin Dependent Kinase 4/6 (cdk4/6) Inhibitor Lee011 (=ribociclib), And (b) The Epidermal Growth Factor Receptor (egfr) Inhibitor Erlotinib, For The Treatment Or Prevention Of Cancer App 20180243304 - Caponigro; Giordano ; et al.	2018-08-30
Combination of PI3K Inhibitor and C-Met Inhibitor App 20150216870 - Caponigro; Giordano ; et al.	2015-08-06
Compositions and methods for treatment of filovirus-mediated diseases Grant 8,475,804 - Johansen , et al. July 2, 2	2013-07-02
Compositions And Methods For Treatment Of Filovirus-mediated Diseases App 20110028564 - Johansen; Lisa M. ; et al.	2011-02-03
Using multiple perturbations to elucidate connectivity in network systems App 20050090992 - Lehar, Joseph ; et al.	2005-04-28
System and method for multidimensional evaluation of combinations of compositions App 20040253642 - Zimmermann, Grant ; et al.	2004-12-16
System and method for multidimensional evaluation of combinations of compositions App 20040253627 - Zimmermann, Grant ; et al.	2004-12-16
Gene expression associated with psychiatric disorders App 20030152972 - Sklar, Pamela ; et al.	2003-08-14

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.